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The International Society for Stem Cell Research hosted an exciting meeting on stem cell-based translational medicine in Florence, Italy
in September 2013. This report gives an overview of recent advances and breakthroughs presented at the meeting.Florence, the cradle of the 14th–17th century European Re-
naissance (French for re-birth), aptly hosted the Interna-
tional Society for Stem Cell Research (ISSCR) Regional
Forum on ‘‘Stem Cells in Translation’’ in September 2013.
Over 300 delegates from 36 countries gathered at the
19th century Villa Vittoria (see Figure 1 for impressions
from the conference) to share their recent findings on
potential clinical applications of stem cells. There is great
hope that stem cells will find multiple applications in
regenerative medicine, perhaps the most obvious being
the replacement of damaged or lost tissue. Cell replace-
ment, however, may not be the only translational route:
in vitro modeling of human development and disease,
drug screening platforms, or the delivery of therapeutic
molecules in vivo were all aspects of translation covered
in the meeting. The meeting would not have been com-
plete without some cautionary notes; specifically, teratoma
risk using pluripotent stem cells or the propensity of adult
stem cells to undergo malignant transformation, as
observed in some experimental tumors and in patients
receiving gene-modified hematopoietic stem cells.
Co-organizer Michele De Luca (University of Modena
and Reggio Emilia, Italy) opened the meeting with a
passionate appeal for rigorous standards in the introduc-
tion of stem cells into the clinic and discussed the potential
damage to the field irresponsible use of unproven therapies
could bring. In his presentation, De Luca gave an example
of what this can mean: the Italian Stamina Foundation
has engaged in treating patients with autologous
mesenchymal stem cell-like cells, which he described as
‘‘based on flawed and fraudulent preclinical tests’’ (see
also Abbot, 2013). He called for stem cell researchers to
actively seek dialog with decision makers in politics and
regulatory agencies, as well as with the general public, to
avoid misrepresentation of treatments under the label of
stem cell therapy. The ISSCR has addressed this issue at
length in their ‘‘Guidelines for the Clinical Translation of
Stem Cells’’ for researchers (http://www.isscr.org/docs/
guidelines/isscrglclinicaltrans.pdf) and patient-directed
website ‘‘A Closer Look at Stem Cell Treatments’’ (http://
www.closerlookatstemcells.org/).486 Stem Cell Reports j Vol. 1 j 486–490 j December 17, 2013 j ª2013 TheStem Cells and Regenerative Medicine
Hope in the future rise of stem cell-based therapies was fu-
eled during this meeting by a series of reports on the suc-
cessful application of stem cells to regenerate lost or
damaged tissues in both preclinical models and in patients.
Tissue-specific stem cells are already showing efficacy in the
clinic, the best known example being allogeneic hemato-
poietic stem cell (HSC) transplantation to reconstitute
functional hematopoiesis in patients. Bobby Gaspar (UCL
Institute of Child Health, UK) and Alain Fischer (CHU
Necker INSERM U768, France) took HSC therapy one step
further and combined autologous HSC transplantation
with gene therapy to treat primary immunodeficiencies.
At the meeting, Gaspar and Fischer summarized the
follow-up of these studies, showing considerable success
in long-term reconstitution of a functional immune system
in patients with severe combined immunodeficiency
(SCID). In the same session, Luigi Naldini (San Raffaele
Scientific Institute, Italy) presented results from pilot
studies in patients suffering frommetachromatic leukodys-
trophy and Wiskott-Aldrich syndrome and showed suc-
cessful gene correction and a clinical benefit in these
patients. Another example of successful clinical applica-
tion of adult stem cells was presented byGraziella Pellegrini
(University of Modena and Reggio Emilia, Italy), who
together with Michele De Luca developed a limbal stem
cells transplantation regime to restore damaged corneal
epithelium in patients with ocular burns. These and other
examples of clinical applications of adult stem cells pre-
sented at the meeting are summarized in Table 1.
Many presentations followed that focused on promising
preclinical studies for potential stem cell therapies, which,
taken together, suggested that clinical translation may
expect significant growth within the coming years.
Notably, therapies based on pluripotent stem cells are
catching up with adult stem cells: Lorenz Studer (Sloan-
Kettering Institute for Cancer Research, USA), for example,
who has carried out research on the derivation of dopami-
nergic neurons from pluripotent stem cells for more than a
decade, revealed his plans for the first clinical trials to treat
Parkinson’s Disease in the coming years.Authors Open access under CC BY-NC-ND license.
Figure 1. Impressions from the ISSCR Regional Meeting in Florence, Italy, in September 2013
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through expansion and differentiation of stem cells
in vitro, through stimulation of endogenous progenitors
in situ, or through direct reprogramming included vascular
endothelial cells, retinal pigment epithelium, hepatocytes
and oligodendrocytes (see Table 1 for a complete list).
Major hurdles for bringing induced pluripotent stem
cells (iPSCs) to the clinic (which also applies to some other
types of stem cells) were discussed byGeorge Daley (Boston
Children’s Hospital, USA): (1) efficient iPSC derivation un-
der GMP conditions, (2) safe methods for genetic modifica-
tion, (3) efficient differentiation and maturation of cells,
and (4) scaling up production to clinically relevant cell
numbers. Daley announced the introduction of a new
cell type classifier, Cell Net, which is an online platform
trained on gene expression data from murine and human
cell types. This platform will allow researchers to discover
gene regulatory networks within the gene expression data
from cells generated in their lab and to compare theirStem Cell Reports j Vol. 1 j 486–490 j December 1in vitro engineered cells with their in vivo counterparts,
with the aim of validating the identity of the cell types
formed and enhancing the efficiency of directed differenti-
ation and direct reprogramming experiments.
Cancer and Stem Cells
Accumulating evidence suggests an intimate link between
stem cells and cancer, although this is still controversial.
The cancer stem cell model suggests that cellular hierar-
chies, much resembling hierarchies in normal tissues, are
active even in malignant tumors, whereby tumor growth
is fueled by a subset of continuously dividing and differen-
tiating cancer stem cells. Furthermore, it has been sug-
gested that cancer stem cells may arise from malignant
transformation of normal tissue stem cells.
In his opening lecture, John Dick (University Health
Network, Canada) followed up on the debate on the origin
of cellular heterogeneity within tumors and whether it re-
sults from the activity of cancer stem cells or from clonal7, 2013 j ª2013 The Authors 487Open access under CC BY-NC-ND license.
Table 1. Applications of Stem Cells in Translational Medicine Presented at This Meeting
Presenter Cells (Re) Generated Method and Starting Cell Population Status Related Publication
Direct Reprogramming
Shahin Rafii Vascular endothelial cells Overexpression of transcription factors
in amniotic cells, TGFb-inhibition
Preclinical (Ginsberg et al., 2012)
Activation of Endogenous Progenitors
Robin Franklin Oligodendrocytes Stimulation of oligodendrocyte
progenitors with systemic factors,
pharmacological compounds
Preclinical (Ruckh et al., 2012;
Yuen et al., 2013)
Mauro Giacca Cardiomyocytes Stimulation of cardiomyocyte
proliferation by in vivo expression
of secreted proteins, miRNAs
Preclinical (Eulalio et al., 2012)
Stuart Forbes Hepatocytes Stimulation of hepatocyte progenitor
cell proliferation/differentiation
by macrophage infusion
Preclinical (Bird et al., 2013;
Boulter et al., 2012)
Regeneration from Adult/Tissue-Specific Stem Cells
Hans Clevers Hepatocytes Organoid culture/ expansion and
transplantation of liver stem cells
Preclinical (Huch et al., 2013)
Graziella Pellegrini Corneal epithelium Culture/expansion and transplantation
of autologous limbal stem cells
in patients with ocular burns
Clinical (Pellegrini et al., 2013;
Rama et al., 2010)
Paolo
Macchiarini
Tracheal epithelium Transplantation of bioartificial trachea seeded
with autologous bone-marrow mononuclear
cells in patient with tracheal cancer
Clinical (Jungebluth et al.,
2011)
Giulio Cossu Skeletal muscle Transplantation of HLA-matched
mesangioblasts via artery infusion
in patients with Duchenne muscular dystrophy
Clinical
Bobby Gaspar Immune system Infusion of gene-modified autologous HSCs
in patients with ADA-SCID and SCID-X1
Clinical (Gaspar et al., 2011a;
Gaspar et al., 2011b)
Alain Fischer Immune system Infusion of gene-modified autologous
HSCs in patients with SCID-X1
Clinical (Hacein-Bey-Abina
et al., 2010)
Luigi Naldini Blood system Infusion of gene-modified autologous HSCs
in patients with Wiskott-Aldrich syndrome
Clinical (Aiuti et al., 2013)
Luigi Naldini Immune system Infusion of gene-modified autologous
HSCs in patients with metachromatic
leukodystrophy
Clinical (Biffi et al., 2013)
Sally Temple Retinal pigment
epithelium (RPE)
Subretinal transplantation of RPE
generated from autologous/allogeneic
RPE stem cells
Preclinical (Salero et al., 2012)
Regeneration from Pluripotent Stem Cells
Lorenz Studer Dopaminergic (DA)
neurons
Directed differentiation of ESCs to DA
neurons via floorplate intermediate
Preclinical (Ganat et al., 2012;
Kriks et al., 2011)
Yoshiki Sasai Neural retina Self-organization of ESCs in vitro,
enhanced thorough Notch inhibition
Preclinical (Nakano et al., 2012)
Gordon Keller Hepatocytes Directed differentiation of ESCs,
maturation with aggregation and cAMP
Preclinical (Ogawa et al., 2013)
Gordon Keller Definitive hematopoietic
progenitors
Directed differentiation of ESCs Preclinical (Kennedy et al., 2012)
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Meeting Reportevolution. Dick suggested that in human leukemias, both
might synergize to drive disease progression. Thus, a subset
of leukemia stem cells (LSCs) would with time acquire mu-
tations, which lead to accelerated proliferation and
decreased apoptosis/chemosensitivity. Notably, the LSC
gene expression signature is highly correlated with the
expression signature of normal HSCs, suggesting that
HSCs are the cell or origin of some leukemias, and that
HSC signature genes might be promising therapeutic tar-
gets (Eppert et al., 2011). Hans Clevers (Hubrecht Institute,
Netherlands) reported that tissue-specific stem cells ex-
pressing theWNT target LGR5 can be found in many adult
tissues, including colon, small intestine, liver, stomach, and
hair follicles. Recent evidence from Clevers’ lab suggests
that LGR5+ stem cells are the target cell of oncogenic trans-
formation in intestinal carcinomas.Likewise, a cellularhier-
archy was observed in these tumors, lending further evi-
dence to the cancer stemcell concept (Schepers et al., 2012).
It is commonly known that undifferentiated pluripotent
stem cells can give rise to tumors, so-called teratomas, and
that undifferentiated stem cells need to be eliminated
before grafting to avoid tumor formation. Even tissue-
specific stemcells can acquire tumorigenic properties under
certain circumstances, as evidenced in someearly gene ther-
apy trials in which insertional mutagenesis in transplanted
HSCs caused leukemias inpatients (Hacein-Bey-Abina et al.,
2008; Howe et al., 2008). Although this observation war-
rants caution for gene and cell therapy strategies, enhanced
safety features in vectors used to deliver the gene therapy
constructs, such as the self-inactivating lentiviral vectors
presentedbyChristopherBaum(HannoverMedical School,
Germany), and improved transduction protocols will mini-
mize the leukemic risk in future patients. Thus, plasticity
and self-renewal of stem cells, and susceptibility to malig-
nant transformation, may be two sides of the same coin
and need to be properly balanced and controlled when
using stem cells in a clinical setting.Conclusions
Stem cell-based preclinical studies and clinical applications
are clearly on the rise, and important breakthroughs in
clinical use of stem cells have been achieved with more to
be expected in the near future. As the field advances at an
ever-growing pace, researchers, clinicians, patients, and
regulatory authorities need to be aware of associated risks
and commit to rigorous preclinical and clinical investiga-
tion to maximize safety and the clinical utility of
treatments.REFERENCES
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